Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years

BACKGROUND: Women with SLE have higher rates of persistent human papilloma virus (HPV) infections and precancerous lesions than healthy women. HPV vaccine is safe and effective in healthy females aged 9–26 years. There are limited data on the safety and immunogenicity of HPV vaccine in females with...

Descripción completa

Detalles Bibliográficos
Autores principales: Soybilgic, Arzu, Onel, Karen B, Utset, Tammy, Alexander, Kenneth, Wagner-Weiner, Linda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751269/
https://www.ncbi.nlm.nih.gov/pubmed/23924237
http://dx.doi.org/10.1186/1546-0096-11-29

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751269/
https://www.ncbi.nlm.nih.gov/pubmed/23924237
http://dx.doi.org/10.1186/1546-0096-11-29

Ejemplares similares